{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:07:08Z","timestamp":1784358428521,"version":"3.55.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["R01-ES029294"],"award-info":[{"award-number":["R01-ES029294"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P30-ES013508"],"award-info":[{"award-number":["P30-ES013508"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10-OD023592"],"award-info":[{"award-number":["S10-OD023592"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016958","name":"National Institutes of Health Office of Research Infrastructure Programs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["PF-24-1291669-01-CDP"],"award-info":[{"award-number":["PF-24-1291669-01-CDP"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.dmd.2025.100142","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:30:53Z","timestamp":1754436653000},"page":"100142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic activation of flunitrazepam via nitroreduction mediated by aldo-keto reductase 1C3"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2955-5304","authenticated-orcid":false,"given":"C\u00e1tia F.","family":"Marques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1941-285X","authenticated-orcid":false,"given":"Maya","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3937-1066","authenticated-orcid":false,"given":"Trevor M.","family":"Penning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2025.100142_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apha.2021.12.001","article-title":"Roles of cytochrome P450 enzymes in pharmacology and toxicology: past, present, and future","volume":"95","author":"Guengerich","year":"2022","journal-title":"Adv Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100142_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1021\/tx500444e","article-title":"Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals","volume":"28","author":"Rendic","year":"2015","journal-title":"Chem Res Toxicol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100142_bib3","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1021\/acs.chemrestox.2c00175","article-title":"Nitroreduction: a critical metabolic pathway for drugs, environmental pollutants, and explosives","volume":"35","author":"Penning","year":"2022","journal-title":"Chem Res Toxicol"},{"issue":"Pt 3","key":"10.1016\/j.dmd.2025.100142_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/bj3260625","article-title":"Comparative anatomy of the aldo-keto reductase superfamily","volume":"326","author":"Jez","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/j.dmd.2025.100142_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cbi.2014.09.024","article-title":"The aldo-keto reductases (AKRs): overview","volume":"234","author":"Penning","year":"2015","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.dmd.2025.100142_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev.pharmtox.47.120505.105337","article-title":"Aldo-keto reductases and bioactivation\/detoxication","volume":"47","author":"Jin","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.dmd.2025.100142_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.111111","article-title":"Aldo-keto reductase (AKR) superfamily website and database: an update","volume":"398","author":"Andress Huacachino","year":"2024","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.dmd.2025.100142_bib8","series-title":"Comprehensive Toxicology","first-page":"164","article-title":"10.08\u2014The aldo-keto reductase superfamily","author":"Penning","year":"2018"},{"issue":"4","key":"10.1016\/j.dmd.2025.100142_bib9","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-09-3237","article-title":"The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3","volume":"70","author":"Guise","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.dmd.2025.100142_bib10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1128\/AAC.47.4.1407-1409.2003","article-title":"In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis","volume":"47","author":"Crowell","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"Supp 1","key":"10.1016\/j.dmd.2025.100142_bib11","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s00436-002-0754-9","article-title":"Nitroheterocyclic drugs with broad spectrum activity","volume":"90","author":"Raether","year":"2003","journal-title":"Parasitol Res"},{"issue":"12","key":"10.1016\/j.dmd.2025.100142_bib12","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.clinthera.2005.12.012","article-title":"Tinidazole: a nitroimidazole antiprotozoal agent","volume":"27","author":"Fung","year":"2005","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.dmd.2025.100142_bib13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/MEG.0b013e3282eeb4cc","article-title":"Liver transplantation for nonsteroidal anti-inflammatory drug-induced liver failure: nimesulide as the first implicated compound","volume":"19","author":"Dastis","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100142_bib14","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1021\/acs.jmedchem.8b00147","article-title":"Nitro-group-containing drugs","volume":"62","author":"Nepali","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.dmd.2025.100142_bib15","first-page":"458","volume":"105","year":"2013"},{"issue":"11","key":"10.1016\/j.dmd.2025.100142_bib16","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1021\/acs.chemrestox.8b00250","article-title":"Role of human aldo-keto reductases in the metabolic activation of the carcinogenic air pollutant 3-nitrobenzanthrone","volume":"31","author":"Murray","year":"2018","journal-title":"Chem Res Toxicol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100142_bib17","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1021\/acs.chemrestox.2c00271","article-title":"Role of human aldo-keto reductases in the nitroreduction of 1-nitropyrene and 1,8-dinitropyrene","volume":"35","author":"Su","year":"2022","journal-title":"Chem Res Toxicol"},{"issue":"Pt 1","key":"10.1016\/j.dmd.2025.100142_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/bj3510067","article-title":"Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones","volume":"351","author":"Penning","year":"2000","journal-title":"Biochem J"},{"issue":"4 Pt 1","key":"10.1016\/j.dmd.2025.100142_bib19","first-page":"460","article-title":"Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4","volume":"29","author":"Kilicarslan","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2025.100142_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw083","article-title":"Optimization of clonazepam therapy adjusted to patient\u2019s CYP3A status and NAT2 genotype","volume":"19","author":"Toth","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100142_bib21","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1124\/dmd.105.008623","article-title":"Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients","volume":"34","author":"Goda","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"2, Supplement","key":"10.1016\/j.dmd.2025.100142_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0090-4295(91)80096-P","article-title":"Pharmacokinetics and metabolism of nilutamide","volume":"37","author":"Creaven","year":"1991","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.dmd.2025.100142_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/00003088-199835040-00001","article-title":"Clinical pharmacokinetics of nimesulide","volume":"35","author":"Bernareggi","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmd.2025.100142_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/096032719901800208","article-title":"The role of nitro-reduction and nitric oxide in the toxicity of chloramphenicol","volume":"18","author":"Holt","year":"1999","journal-title":"Hum Exp Toxicol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100142_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1472-8206.1993.tb00219.x","article-title":"Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism","volume":"7","author":"Seree","year":"1993","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.dmd.2025.100142_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.abb.2018.10.017","article-title":"Substrate selectivity of human aldehyde oxidase 1 in reduction of nitroaromatic drugs","volume":"659","author":"Ogiso","year":"2018","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"10.1016\/j.dmd.2025.100142_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000137306","article-title":"Long-term sleep laboratory evaluation of flunitrazepam","volume":"19","author":"Scharf","year":"1979","journal-title":"Pharmacology"},{"issue":"6","key":"10.1016\/j.dmd.2025.100142_bib28","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3109\/10826089709039372","article-title":"Rohypnol misuse in the United States","volume":"32","author":"Saum","year":"1997","journal-title":"Subst Use Misuse"},{"issue":"2","key":"10.1016\/j.dmd.2025.100142_bib29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00004714-200304000-00009","article-title":"The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo","volume":"23","author":"Gafni","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100142_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1124\/dmd.108.024521","article-title":"Metabolic activation of benzodiazepines by CYP3A4","volume":"37","author":"Mizuno","year":"2009","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2025.100142_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/15287390490264767","article-title":"NADPH-cytochrome P-450 reductase is involved in flunitrazepam reductive metabolism in Hep G2 and Hep 3B cells","volume":"67","author":"Peng","year":"2004","journal-title":"J Toxicol Environ Health A"},{"issue":"5","key":"10.1016\/j.dmd.2025.100142_bib32","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1021\/jm201547v","article-title":"Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17beta-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships","volume":"55","author":"Adeniji","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.dmd.2025.100142_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.01.001","article-title":"A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: head to head comparison with other advanced AKR1C3 targeted therapeutics","volume":"192","author":"Wangtrakuldee","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"19","key":"10.1016\/j.dmd.2025.100142_bib34","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.1021\/bi972725u","article-title":"Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione","volume":"37","author":"Burczynski","year":"1998","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.dmd.2025.100142_bib35","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.freeradbiomed.2011.12.007","article-title":"Prevention of salt-induced renal injury by activation of NAD(P)H:quinone oxidoreductase 1, associated with NADPH oxidase","volume":"52","author":"Kim","year":"2012","journal-title":"Free Radic Biol Med"},{"issue":"7","key":"10.1016\/j.dmd.2025.100142_bib36","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/jms.1777","article-title":"MassBank: a public repository for sharing mass spectral data for life sciences","volume":"45","author":"Horai","year":"2010","journal-title":"J Mass Spectrom"},{"key":"10.1016\/j.dmd.2025.100142_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2024.106641","article-title":"Specific and potent inhibition of steroid hormone pre-receptor regulator AKR1C2 by perfluorooctanoic acid: implications for androgen metabolism","volume":"246","author":"Huacachino","year":"2025","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"9","key":"10.1016\/j.dmd.2025.100142_bib38","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/2767-9764.CRC-23-0235","article-title":"AKR1C3 converts castrate and post-abiraterone DHEA-S into testosterone to stimulate growth of prostate cancer cells via 5-androstene-3beta,17beta-diol","volume":"3","author":"Detlefsen","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"2","key":"10.1016\/j.dmd.2025.100142_bib39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"issue":"1","key":"10.1016\/j.dmd.2025.100142_bib40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.dmd.2025.100142_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: an open chemical toolbox","volume":"3","author":"O\u2019Boyle","year":"2011","journal-title":"J Cheminform"},{"issue":"16","key":"10.1016\/j.dmd.2025.100142_bib42","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J Comput Chem"},{"issue":"25","key":"10.1016\/j.dmd.2025.100142_bib43","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/jcc.23354","article-title":"CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data","volume":"34","author":"Huang","year":"2013","journal-title":"J Comput Chem"},{"issue":"2","key":"10.1016\/j.dmd.2025.100142_bib44","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J Chem Phys"},{"issue":"18","key":"10.1016\/j.dmd.2025.100142_bib45","doi-asserted-by":"crossref","DOI":"10.1063\/5.0006002","article-title":"Psi4 1.4: open-source software for high-throughput quantum chemistry","volume":"152","author":"Smith","year":"2020","journal-title":"J Chem Phys"},{"issue":"21","key":"10.1016\/j.dmd.2025.100142_bib46","doi-asserted-by":"crossref","first-page":"9620","DOI":"10.1021\/ja00074a030","article-title":"Application of RESP charges to calculate conformational energies, hydrogen bond energies, and free energies of solvation","volume":"115","author":"Cornell","year":"1993","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.dmd.2025.100142_bib47","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.scijus.2011.08.007","article-title":"Rapid determination of flunitrazepam in alcoholic beverages by desorption electrospray ionization-mass spectrometry","volume":"52","author":"D\u2019Aloise","year":"2012","journal-title":"Sci Justice"},{"issue":"2","key":"10.1016\/j.dmd.2025.100142_bib48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.aca.2003.11.034","volume":"506","author":"Smyth","year":"2004","journal-title":"Anal Chim Acta"},{"issue":"21","key":"10.1016\/j.dmd.2025.100142_bib49","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1002\/1097-0231(20001115)14:21<2061::AID-RCM135>3.0.CO;2-8","article-title":"A study of the electrospray ionisation of pharmacologically significant 1,4-benzodiazepines and their subsequent fragmentation using an ion-trap mass spectrometer","volume":"14","author":"Smyth","year":"2000","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"4","key":"10.1016\/j.dmd.2025.100142_bib50","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.gpb.2013.04.001","article-title":"Quantitative evaluation of aldo-keto reductase expression in hepatocellular carcinoma (HCC) cell lines","volume":"11","author":"Yang","year":"2013","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"6","key":"10.1016\/j.dmd.2025.100142_bib51","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/jm3017656","article-title":"Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17beta-hydroxysteroid dehydrogenase\/prostaglandin F synthase) in castrate-resistant prostate cancer","volume":"56","author":"Liedtke","year":"2013","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.dmd.2025.100142_bib52","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s10637-014-0130-5","article-title":"In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17betaHSD5; AKR1C3)","volume":"32","author":"Kikuchi","year":"2014","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.dmd.2025.100142_bib53","series-title":"Drug Transporters","first-page":"29","article-title":"In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy","author":"Burckhardt","year":"2011"},{"issue":"3","key":"10.1016\/j.dmd.2025.100142_bib54","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1124\/dmd.115.066944","article-title":"Diclofenac and its acyl glucuronide: determination of in vivo exposure in human subjects and characterization as human drug transporter substrates in vitro","volume":"44","author":"Zhang","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2025.100142_bib55","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/jps.24468","article-title":"A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design","volume":"104","author":"Poulin","year":"2015","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.dmd.2025.100142_bib56","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/clpt.1983.126","article-title":"Kinetics of five benzodiazepine hypnotics in healthy subjects","volume":"34","author":"Jochemsen","year":"1983","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2025.100142_bib57","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1248\/bpb.25.441","article-title":"Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines","volume":"25","author":"Usami","year":"2002","journal-title":"Biol Pharm Bull"},{"issue":"45","key":"10.1016\/j.dmd.2025.100142_bib58","doi-asserted-by":"crossref","first-page":"13451","DOI":"10.1021\/bi026109w","article-title":"Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2)","volume":"41","author":"Trauger","year":"2002","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/j.dmd.2025.100142_bib59","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1021\/acschemneuro.3c00131","article-title":"Effects of pregnanolone glutamate and its metabolites on GABAA and NMDA receptors and zebrafish behavior","volume":"14","author":"Abramova","year":"2023","journal-title":"ACS Chem Neurosci"},{"issue":"16","key":"10.1016\/j.dmd.2025.100142_bib60","doi-asserted-by":"crossref","first-page":"8857","DOI":"10.3390\/ijms25168857","article-title":"5\u03b2-Dihydrosteroids: formation and properties","volume":"25","author":"Penning","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.dmd.2025.100142_bib61","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/mp.2017.4","article-title":"Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice","volume":"22","author":"Busquets-Garcia","year":"2017","journal-title":"Mol Psychiatry"},{"issue":"21","key":"10.1016\/j.dmd.2025.100142_bib62","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.1523\/JNEUROSCI.0281-09.2009","article-title":"Pregnanolone sulfate promotes desensitization of activated NMDA receptors","volume":"29","author":"Kussius","year":"2009","journal-title":"J Neurosci"},{"issue":"1\u20132","key":"10.1016\/j.dmd.2025.100142_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neulet.2003.12.124","article-title":"Perinatal flunitrazepam exposure causes persistent alteration of parvalbumin-immunoreactive interneuron localization in rat prefrontal cortex","volume":"359","author":"Grobin","year":"2004","journal-title":"Neurosci Lett"},{"issue":"18","key":"10.1016\/j.dmd.2025.100142_bib64","doi-asserted-by":"crossref","first-page":"11723","DOI":"10.1074\/jbc.272.18.11723","article-title":"Flunitrazepam has an inverse agonistic effect on recombinant alpha6beta2gamma2-GABAA receptors via a flunitrazepam-binding site","volume":"272","author":"Hauser","year":"1997","journal-title":"J Biol Chem"},{"issue":"12 Suppl","key":"10.1016\/j.dmd.2025.100142_bib65","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1002\/1097-0142(19931215)72:12+<3828::AID-CNCR2820721712>3.0.CO;2-U","article-title":"Pharmacology of nilutamide","volume":"72","author":"Gaillard-Moguilewsky","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.dmd.2025.100142_bib66","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jsbmb.2013.05.012","article-title":"AKR1C3 as a target in castrate resistant prostate cancer","volume":"137","author":"Adeniji","year":"2013","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100142_bib67","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s42004-024-01177-4","article-title":"Discovery of an aldo-keto reductase 1C3 (AKR1C3) degrader","volume":"7","author":"Carmona","year":"2024","journal-title":"Commun Chem"},{"issue":"11","key":"10.1016\/j.dmd.2025.100142_bib68","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.3390\/ijms22115495","article-title":"The role of HPA axis and allopregnanolone on the neurobiology of major depressive disorders and PTSD","volume":"22","author":"Almeida","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:14:42Z","timestamp":1772817282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625091512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0090955625091512"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100142","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic activation of flunitrazepam via nitroreduction mediated by aldo-keto reductase 1C3","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100142"}}